Method, composition and device for sampling natriuretic peptides in a biological fluid
View Patent ↗Disclosed is a composition that synergistically prevents proteolysis or modification of peptides in sampled biological fluids using sulfonyl fluoride family protease inhibitors at high concentrations combined with at least one additional protease inhibitor of a different type, preferably a broad spectrum protease inhibitor, and a chelator. A preferred embodiment uses AEBSF at 10 mM, Benzamidine at 20 mM and EDTA as the chelator. The disclosed composition may be combined with other protease inhibitors to further modulate its specificity, for instance to additionally target acidic proteases. Additional protease inhibitors, reducing agents, stabilizers and buffering agents may be combined with the disclosed compositions in devices for sampling or testing biological fluids for levels of peptides of interest, or methods therefore. The disclosed devices, compositions and methods are of particular use in sampling and testing for the level of natriuretic peptides.
1. A method of sampling a protein profile in a biological fluid of interest, comprising:
adding an effective amount of chelator to a sample of the biological fluid;
adding an effective amount of a first protease inhibitor selected from the group consisting of leupeptin and benzamidine; and
adding a second protease inhibitor, based on sulfonyl fluoride, suitable for inactivating serine proteases, at a concentration of about 10 mM, whereby the sampled protein profile is essentially unmodified by the formation of adducts by a combination of the effective amount of the first protease inhibitor and the second protease inhibitor in combination.
2. A method according to claim 1 , wherein a fluid fraction of the sampled biological fluid is stored at one or more of seventy degrees centigrade below zero, below zero degrees centigrade, at two to four degrees centigrade, and room temperature.
3. A method according to claim 1 , wherein the biological fluid is sampled by adding the chelator followed by one or more of the first protease inhibitor and the second protease inhibitor.
4. A method according to claim 1 , wherein the biological fluid is blood or urine.
5. A method according to claim 1 , wherein the second protease inhibitor is AEBSF.
6. A method according to claim 5 , wherein AEBSF is at a concentration of about 10 mM and benzamidine is at a concentration of about 20 mM in a sampled biological fluid; or AEBSF is at a concentration of about 2.5 mM and leupeptin is at a concentration of about 2.5 mM.
7. A method according to claim 1 , wherein the second protease inhibitor is AEBSF present at a concentration of about 10 mM and benzamidine is at a concentration of about 20 mM in the sampled biological fluid, or AEBSF is at a concentration of about 2.5 mM and leupeptin as the second protease inhibitor is at a concentration of about 2.5 mM.